HRT Clinic Lab Panels: Tests, Timing, and 3 to 6 Month Monitoring

An HRT clinic lab panel is a focused set of serum tests used to establish baseline safety and to guide dosing and monitoring. The core analytes clinicians rely on most often are estradiol, total and free testosterone, FSH, LH, and a baseline safety panel covering CBC, liver function, and lipids. Guidance from the Endocrine Society and The North American Menopause Society shapes how these results translate into treatment decisions, and we work alongside clinics to make that testing reliable and well documented.

TL;DR:

• Serum testing for hormones is preferred over saliva and urine due to greater reliability and guideline support.
• Baseline tests include estradiol, total testosterone, FSH, LH, CBC, liver function, and lipids, tailored to each patient’s therapy and risk factors.
• Hormone levels are interpreted in context, requiring repeating measurements and detailed collection metadata to avoid misdiagnosis.
• Timing and specimen collection procedures, such as fasting and morning draws, are critical to ensuring accurate and comparable hormone results.
• Monitoring schedules vary, with more frequent testing during the first year of therapy and adjustments based on individual risk, medication, and assay consistency.

Which tests are commonly ordered on HRT clinic hormone panels

The right panel depends on the patient and the therapy, but most HRT clinics build from a consistent core of analytes, then add tests based on symptoms, sex, and risk factors.

• Estradiol and total testosterone form the baseline sex-hormone picture for both men and women starting hormone therapy.
• Free testosterone or SHBG becomes useful when total testosterone sits near a diagnostic threshold or when binding protein changes (from obesity, thyroid disease, or liver disease) might distort the total value.
• FSH and LH help distinguish primary from secondary hypogonadism and confirm menopausal status when the clinical picture is unclear.
• AMH adds value in specific fertility-related or reproductive-axis evaluations, though it is not a routine part of most HRT monitoring.
• CBC and hematocrit catch erythrocytosis risk before and during testosterone therapy.
• CMP or LFTs, fasting lipids, and fasting glucose or HbA1c establish metabolic and hepatic baselines that influence whether therapy is appropriate and how closely a patient needs follow-up.
• Creatinine and electrolytes flag renal function issues that can affect both candidacy and dosing.
• DHEA-S, cortisol, and a thyroid panel (TSH, free T4, and antibodies when indicated) rule out adrenal or thyroid contributors to symptoms that otherwise mimic hormonal imbalance.

Serum testing remains the standard for dosing decisions because it reflects circulating hormone levels in a way that correlates with clinical outcomes and guideline-based thresholds. Saliva and urine testing, by contrast, introduce variability that major societies specifically caution against for treatment decisions, a point we return to below.

How clinics use lab results to guide HRT

Lab values rarely stand alone. A single low testosterone reading does not make a diagnosis, and a single estradiol number should not dictate a dose change. The Endocrine Society guideline is explicit that confirming male hypogonadism requires compatible symptoms plus consistently low morning testosterone on repeat measurement, not a single borderline result.

Before initiating therapy, baseline safety checks can delay or redirect the treatment plan altogether. Elevated hematocrit, abnormal liver function, or poorly controlled lipids and glucose often prompt a conversation about risk before a prescription is written. Once therapy starts, dose titration should prioritize symptom relief and safety over chasing a specific numeric target, a stance NAMS reinforces for menopausal hormone therapy: clinical response and risk profile matter more than an isolated estradiol value.

Certain findings should trigger additional workup or referral:

1. A rising hematocrit during testosterone therapy warrants dose adjustment or a pause before it becomes a safety issue.
2. A PSA increase greater than 1.4 ng/mL within the first year, or any value exceeding 4.0 ng/mL, should prompt urology referral per Endocrine Society guidance.
3. Persistent liver enzyme elevation on a compounded or oral regimen should prompt a formulation review.
4. Unexplained symptom persistence despite therapeutic-range labs should prompt a look at adherence, timing, or assay reliability rather than an automatic dose increase.

Every requisition should carry enough context for the result to mean something later: indication, route, dose, time since last dose, collection time, and assay method. Without that metadata, a number on a trend line is just a number.

Pro Tip: Build a standing requisition template for HRT visits that forces entry of collection time and dose timing, so no result arrives without the context needed to interpret it.

Timing, specimen collection, and assay considerations that change interpretation

The same patient can produce meaningfully different testosterone results depending on when and how the sample is drawn. Morning collection is standard practice for testosterone because of diurnal variation, and timing relative to a topical application or injection changes whether a result reflects a peak, a trough, or something in between.

• Morning fasting draws are typically requested for testosterone and metabolic panels to reduce variability from diurnal rhythm and recent food intake.
• Topical and injectable regimens produce predictable peaks and troughs, so the clinical question (is this a trough level, a mid-cycle level, or a peak) should be answered before ordering.
• Documented collection metadata (dose timing, sample time, route) turns a single value into something that can be trended reliably over successive visits.
• Consistent lab and assay choice across visits matters as much as the timing itself, since switching methods mid-treatment can look like a clinical change that is really just a measurement artifact.

Immunoassay and LC-MS/MS methods do not always agree, particularly at the low end of the testosterone range. The Endocrine Society notes that nonstandardized assays can classify the same sample as low or normal depending on the method used, which is why CDC HoST-certified assays are preferred when precision at low concentrations matters, such as testing women or monitoring low-range male results.

Saliva and urine hormone testing are discouraged by NAMS and other major societies for guiding HRT dosing, largely because they do not correlate reliably with the serum thresholds that guidelines and dosing protocols are built around.

Recommended monitoring schedules by therapy type

Monitoring intervals differ by therapy, and matching the schedule to the regimen avoids both under-monitoring and unnecessary repeat testing.

Baseline testing before initiation is consistent across regimens even when follow-up intervals differ: a CBC and liver panel before starting therapy catches most of the safety issues that would otherwise surface later as an unexplained lab abnormality.

Interpreting results: common pitfalls, assay variability, and management triggers

The most common interpretation error is treating an estradiol or testosterone number as a target rather than a data point. NAMS is direct about this for menopausal therapy: routine hormone testing is not required to decide who should start treatment, and symptom response generally matters more than hitting a specific estradiol level.

• Chasing a numeric target for menopausal symptom control can lead to dose escalation that outpaces symptom benefit and increases risk without added relief.
• Assay variability means a result flagged low on one platform might read differently on another, which is why trending on the same assay, ideally a CDC HoST-certified method, matters more than comparing results across different labs.
• Hematocrit and PSA thresholds give a concrete basis for action: a hematocrit rise or a PSA increase over the thresholds the Endocrine Society specifies warrants a dose change, a pause, or referral rather than a wait-and-see approach.
• Compounded products and pellet therapy carry more variability in delivered dose, so clinics that use them may find additional testing more useful than they would with FDA-approved, standardized formulations.

Pro Tip: When a result looks inconsistent with the clinical picture, repeat it on the same assay before changing the dose. A single outlier value is more often a measurement issue than a treatment failure.

Ordering, specimen logistics, turnaround, and cost considerations for clinics

Ordering decisions affect both clinical accuracy and clinic workflow. A bundled panel saves ordering time but can include analytes that will not change management; a discrete-test approach takes more thought but keeps costs and result volume proportional to the clinical question.

• Choose panel versus discrete tests based on whether each analyte will actually influence the visit’s decision, not just because a bundle is available.
• Include clinical indication and collection metadata on every requisition so the result arrives ready to interpret, not just ready to file.
• Specimen pickup and courier arrangements should be specified in any lab contract, along with expected turnaround and how results reach the EHR.
• LC-MS/MS and other specialty assays often carry higher out-of-pocket costs than standard immunoassays, which is worth raising with patients before the draw, not after the bill arrives.

KoHealth Labs: lab capabilities and provider services for HRT clinics

We built our testing menu around the panels HRT clinics actually need: hormone panels, thyroid testing, and the specialty assays that round out a safety workup, alongside specimen pickup, electronic results delivery, and LIS or EHR integration.

• We support documentation of assay method and collection metadata on every order to keep trending reliable across visits.
• We offer downloadable hormone panel references and thyroid testing details that clinics can use when deciding how to structure an order.
• We work with practices on onboarding and specimen pickup scheduling so testing fits smoothly into clinical workflows.

Some clinics use us as a supplemental lab alongside existing laboratory relationships, often seeking faster turnaround or more personalized support on complex panels.

Patient preparation recommendations to improve accuracy of hormone lab results

Preparation affects hormone results more than many patients realize, and a few simple instructions before the draw can prevent a confusing or misleading result. Fasting is typically requested for lipid panels and glucose or HbA1c testing, and extending that same fasting window to a testosterone draw avoids the variability that a recent meal can introduce into metabolic markers drawn at the same visit.

Morning collection matters for testosterone given its diurnal pattern, so scheduling the draw early and consistently across visits improves comparability over time. Patients on biotin supplements should be told to stop at least 48 hours before a thyroid or hormone panel, since biotin can interfere with certain immunoassay platforms and produce artificially skewed results.

Timing relative to medication dosing deserves its own conversation. A patient on transdermal testosterone who showers immediately before a draw, or one who times a blood test right after an injection rather than at a trough point, can produce a result that looks nothing like their steady-state level. Clinics that standardize instructions, same time of day, same fasting status, same relationship to the last dose, make it far easier to trust a trend line rather than chase noise.

Specific lab panel differences for various patient populations under HRT

Panel composition shifts meaningfully depending on who is being treated. For hypogonadal men, the core workup centers on total and free testosterone, LH and FSH to localize the cause, and hematocrit plus PSA for ongoing safety monitoring once therapy begins.

For menopausal women, routine hormone testing is often unnecessary, as NAMS notes; symptom response guides most dosing decisions. Testing becomes more relevant for women using compounded bioidentical regimens or pellet therapy, where delivered dose is less predictable than with FDA-approved products.

For transgender and gender-diverse individuals, ACOG guidance outlines monitoring testosterone and hematocrit every three months during the first year of masculinizing therapy, with estradiol, testosterone, SHBG, albumin, and electrolytes tracked for feminizing regimens when clinically indicated. These schedules reflect the different pharmacokinetics and risk profiles of masculinizing versus feminizing hormone therapy rather than a single universal protocol.

Women evaluated for HSDD and treated with testosterone fall into their own category, with The Menopause Society recommending baseline total testosterone and SHBG, then repeat testing at 3 to 6 weeks after a dose change and every 4 to 6 months once stable.

Potential drug interactions and conditions that can affect lab results and their interpretation

Several common medications and conditions can distort hormone results in ways that lead to misdiagnosis if they go unrecognized. Oral estrogen and some anticonvulsants raise SHBG, which lowers free testosterone even when total testosterone looks normal, a pattern that can mimic hypogonadism on a total-only panel. Opioids suppress the hypothalamic-pituitary-gonadal axis and can lower testosterone and LH independent of any underlying reproductive issue, so a thorough medication history belongs alongside any hypogonadism workup.

Obesity and insulin resistance lower SHBG and complicate interpretation of total testosterone in both directions depending on the analyte. Thyroid dysfunction, whether hyperthyroid or hypothyroid, alters SHBG and can produce symptoms, like fatigue or mood changes, that overlap with hormonal imbalance, which is part of why a thyroid panel belongs in most HRT workups rather than being treated as optional.

Liver disease changes SHBG production directly and affects clearance of exogenous hormones, so abnormal liver function on a baseline panel is not just a safety flag, it is also a reason to interpret hormone levels more cautiously. Biotin supplementation, as noted above, can interfere with immunoassay-based testing across multiple analytes, not just thyroid studies, and should be addressed before any panel that includes immunoassay-based hormone testing.

Why lab quality and partnership matter

Good HRT care depends on results clinicians can trust, which means standardized assays, documented collection metadata, and consistent lab relationships over time. When a clinic and a lab communicate clearly about method, timing, and indication, fewer results get second-guessed and fewer patients get an unnecessary repeat draw. That collaboration is less about any single test and more about building a workflow where every number already carries the context it needs.

— Kohealth Labs

Get started with KoHealth Labs

We make it straightforward to add reliable hormone testing to an HRT practice: review our hormone panel capabilities to see the full testing menu, then schedule a specimen pickup to start sending samples our way.

Clinics that want on-site collection support can also request mobile phlebotomy to fit draws around existing appointment schedules.

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

What labs should be drawn for HRT?

Most HRT workups start with estradiol, total testosterone, FSH, and LH, plus baseline safety labs like CBC, liver function, and fasting lipids. Additional tests such as free testosterone, SHBG, DHEA-S, or a thyroid panel get added based on symptoms and sex-specific guidance.

What labs are in a hormone panel?

A typical hormone panel includes estradiol, total and sometimes free testosterone, FSH, LH, and often DHEA-S and a thyroid panel (TSH, free T4, and antibodies when indicated). The exact combination depends on whether the patient is male, female, or pursuing gender-affirming therapy.

How much does it cost to get a full hormone panel?

Cost varies by which analytes are ordered, the assay method used, and insurance coverage, with specialty methods like LC-MS/MS generally costing more out of pocket than standard immunoassays. Pricing for specific panels is best confirmed directly with the ordering lab, since it depends on the exact test menu and payer arrangement.

Do doctors do blood tests before prescribing HRT?

Yes, baseline blood testing is standard before starting HRT to confirm the diagnosis and check for safety issues like abnormal liver function, elevated hematocrit, or poorly controlled lipids and glucose. The Endocrine Society specifically recommends confirming low testosterone with repeat morning testing before initiating treatment in men.

Sources

• Full Guideline: Testosterone Therapy in Men With Hypogonadism (Endocrine Society)
• Practice pearl: monitoring testosterone in women (The Menopause Society)